by Maeve Luthin, JD, Professional Development Manager
In June’s Association for Molecular Pathology v. Myriad Genetics, Inc. (Myriad) decision, the Supreme Court determined that human genes fall within the “laws of nature” exception to patentable material. This decision invalidated Myriad’s exclusive claim to BRCA 1 and BRCA 2 tests that can be used in determining a woman’s risk in contracting breast and ovarian cancer. However, Myriad wasn’[...] Read more
TAG ARCHIVES FOR current events
by Maeve Luthin, JD, Professional Development Manager
There’s never a summer lull in science! Whether you are at the office basking in air conditioned glory or on vacation soaking up some rays, catch up with the latest news in research ethics by reading this week’s Research Ethics Roundup.
Do Clinical Trials Work?: In this New York Times op-ed piece, [...] Read more
by Elisa A. Hurley, PhD, Education Director
Those who have been following the Surfactant, Positive Pressure, and Oxygenation Randomized Trial (SUPPORT) controversy know that the story has continued to unfold over the past month. Here I review several of the latest developments, some of which may have wide implications for the human research protections [...] Read more
by Maeve Luthin, JD, Professional Development Manager
Catch up on the events of the past two weeks in the research ethics world! Whether you read this edition right away or save the stories for later, spend some time learning about what your colleagues have been up to.
Unlikely Partners: The New York Times[...] Read more
Research Ethics Roundup: The SUPPORT trial debate continues, avian flu makes news, and more
Tags:by Maeve Luthin, JD, Project Coordinator
It’s been a busy two weeks in the research ethics world! Grab some iced coffee and take some time to catch up with current events.
Dirty Medicine: Earlier this month, generic drug manufacturer Ranbaxy pled guilty to federal criminal charges of selling adulterated drugs with the [...] Read more